[HTML] ashpublications.orgFull View

[HTML][HTML] How I treat refractory CRS and ICANS after CAR T-cell therapy

MD Jain, M Smith, NN Shah - … Journal of the American Society of …, 2023 - ashpublications.org
The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …
被引用次数：52 相关文章

How I treat refractory CRS and ICANS after CAR T-cell therapy

MD Jain, M Smith, NN Shah - … Journal of the American Society of …, 2023 - ashpublications.org
The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …
[HTML] nih.gov

[HTML][HTML] How I treat refractory CRS and ICANS after CAR T-cell therapy

MD Jain, M Smith, NN Shah - Blood, 2023 - ncbi.nlm.nih.gov
The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …

How I treat refractory CRS and ICANS following CAR T-cell Therapy

MD Jain, M Smith, NN Shah - Blood, 2023 - Elsevier
(179 words, 200-word limit) The clinical use of chimeric antigen receptor (CAR) T-cell
therapy is growing rapidly due to expanding indications for standard of care treatment and …

How I treat refractory CRS and ICANS after CAR T-cell therapy

MD Jain, M Smith, NN Shah - Blood, 2023 - pubmed.ncbi.nlm.nih.gov
The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …